MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,741,000K
Net Income
$241,900K
Net Profit Margin
13.89%
EPS
$0.42
Unit: Thousand (K) dollars
Revenue Breakdown
United States Segment
Europe Segment
Rest Of World Segment
Japan Segment
Revenue Breakdown
Transcatheter Aortic Valve Repla...
Surgical
Transcatheter Mitral And Tricusp...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net sales
1,741,000
1,648,600
1,569,600
1,553,100
Cost of sales
392,400
362,600
343,000
345,200
Gross profit
1,348,600
1,286,000
1,226,600
1,207,900
Selling, general, and administrative expenses
561,200
522,200
602,900
514,600
Research and development expenses
278,900
263,300
267,700
280,700
Certain litigation expenses
6,300
37,100
208,600
90,400
Change in fair value of contingent consideration liabilities (note 13)
-
-
25,000*
-12,500
Restructuring charges and separation costs (note 3)
-
-
-
100
Restructuring charges, separation costs, and other (note 4)
-
-
4,775*
-
Intangible assets impairment charges
-
-
-19,175*
40,000
Separation costs
0
0
-
-
Other operating income
11,000
14,200
14,300
12,500
Operating income, net
513,200
477,600
151,100
307,100
Interest expense
-
-
5,100*
-
Interest income, net
30,000
33,500
53,000*
38,600
Loss on impairment (note 6)
40,000
123,600
111,800*
0
Other non-operating (income) expense, net (note 7)
16,600
71,500
3,200
2,700
Income from continuing operations before provision for income taxes
519,800
459,000
90,400
348,400
Provision for income taxes
278,400
78,300
26,200
56,100
Net income from continuing operations
241,400
380,700
64,200
292,300
Net sales
-
-
-
15,900
Cost of sales
-
-
-
9,200
Gross profit
-
-
-
6,700
Selling, general, and administrative expenses
-
-
-
5,900
Research and development expenses
-
-
-
1,400
Separation costs
-
-
-
1,900
Operating loss, net
-
-
-
-2,500
Other non-operating (income) expense, net
-
-
-
0
(loss) income from discontinued operations before provision for income taxes
-
-
-
-2,500
(benefit) provision from income taxes from discontinued operations
-
-
-
-500
Loss from discontinued operations, net of tax
0
0
27,000
-2,000
Net income
241,400
380,700
91,200
290,300
Less net loss attributable to noncontrolling interest
-500
0
0
-800
Net income attributable to edwards lifesciences corporation
241,900
380,700
91,200
291,100
Basic EPS
0.42
0.66
0.157
0.5
Diluted EPS
0.42
0.66
0.157
0.5
Basic Average Shares
576,400,000
579,200,000
580,600,000
584,700,000
Diluted Average Shares
577,600,000
580,700,000
581,800,000
585,700,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
United States Segment
$1,003,500K
(12.79%↑ Y/Y)
Europe Segment
$439,600K
(16.23%↑ Y/Y)
Rest Of World Segment
$201,500K
(19.23%↑ Y/Y)
Japan Segment
$96,400K
(1.15%↑ Y/Y)
Net sales
$1,741,000K
(13.63%↑ Y/Y)
Gross profit
$1,348,600K
(13.54%↑ Y/Y)
Other operating
income
$11,000K
(-48.36%↓ Y/Y)
Cost of sales
$392,400K
(13.94%↑ Y/Y)
Operating income, net
$513,200K
(24.81%↑ Y/Y)
Interest income, net
$30,000K
(-19.79%↓ Y/Y)
Selling, general, and
administrative expenses
$561,200K
(11.79%↑ Y/Y)
Research and development
expenses
$278,900K
(0.98%↑ Y/Y)
Other non-operating
(income) expense, net...
$16,600K
(1376.92%↑ Y/Y)
Certain litigation
expenses
$6,300K
(-59.35%↓ Y/Y)
Income from continuing
operations before...
$519,800K
(29.89%↑ Y/Y)
Loss on impairment
(note 6)
$40,000K
Net income from
continuing operations
$241,400K
(-28.13%↓ Y/Y)
Provision for income taxes
$278,400K
(332.97%↑ Y/Y)
Net income
$241,400K
(-27.18%↓ Y/Y)
Less net loss
attributable to...
-$500K
(70.59%↑ Y/Y)
Net income
attributable to edwards...
$241,900K
(-27.40%↓ Y/Y)
Buy us a coffee
logo (34)-svg
Edwards Lifesciences Corp (EW)
logo (34)-svg
Edwards Lifesciences Corp (EW)